CONTEXT

Chronic myeloid leukemia (CML) is a cancer of blood cells, characterized by replacement of the bone marrow with malignant, leukemic cells. Many of these leukemic cells can be found circulating in the blood and can cause enlargement of the spleen, liver, and other organs.

Many approaches have been initiated to the treatment of CML. Yet, about 20 % of these treatments fail in efficiency because of resistance to some medicines.

Dr. TURCQ’s team works on predictive marker of resistance to treatment of CML.